EXTON, Pa., Feb. 14 /PRNewswire-FirstCall/ -- Isolagen, Inc. today announced that it has been invited to present at the 19th Annual Roth Capital Partners OC Conference on Wednesday, February 21, 2007 at 8:30 a.m. PST at the Ritz-Carlton Laguna Niguel in Dana Point, California. The presentation will be webcast live and can be accessed by visiting the investor relations section of the Company’s website at www.isolagen.com.
The presentation will be given by Nicholas L. Teti, Jr., Chairman and Chief Executive Officer of Isolagen. A replay will be available on the Isolagen website after the presentation and will be archived for 30 days.
About Isolagen, Inc.
Isolagen specializes in the development and commercialization of autologous cellular therapies for soft and hard tissue regeneration. The company’s product candidates are based on its proprietary Isolagen Process. Autologous cellular therapy is the process whereby a patient’s own cells are extracted, allowed to multiply and then injected into the patient. Isolagen’s product candidates are designed to be minimally invasive and non-surgical. For additional information, please visit: http://www.isolagen.com.
All statements in this news release that are not based on historical fact are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. While management has based any forward-looking statements contained herein on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties, and other factors, many of which are outside of our control, that could cause actual results to materially differ from such statements. Such risks, uncertainties, and other factors include, but are not necessarily limited to, those set forth under Item 1A “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2005, as updated in “Item 1A. Risk Factors” in the Company’s Quarterly Reports on Form 10-Q. We operate in a highly competitive and rapidly changing environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. We disclaim any intention to, and undertake no obligation to, update or revise any forward-looking statements. Readers are also urged to carefully review and consider the other various disclosures in the Company’s Annual Report on Form 10-K for the year ended December 31, 2005, as well as other public filings with the SEC since such date.
Isolagen, Inc.
CONTACT: Investors, Charles Huiner, of Isolagen, Inc., +1-484-713-6200, orchuiner@isolagen.com
Web site: http://www.isolagen.com/
